ReviewThe patient2016

Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.

Tatjana E MacLeod et al.PubMed ↗Publisher ↗

No numbers read from the abstract.